Compare RXT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXT | MDWD |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 224.6M |
| IPO Year | 2020 | 2014 |
| Metric | RXT | MDWD |
|---|---|---|
| Price | $0.76 | $18.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $1.61 | ★ $37.50 |
| AVG Volume (30 Days) | ★ 1.1M | 112.0K |
| Earning Date | 02-19-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,688,500,000.00 | $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | $1.63 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $0.79 | $14.14 |
| 52 Week High | $3.03 | $22.51 |
| Indicator | RXT | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 26.49 | 50.78 |
| Support Level | $0.96 | $16.25 |
| Resistance Level | $1.05 | $19.70 |
| Average True Range (ATR) | 0.06 | 0.80 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 3.04 | 50.14 |
Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.